Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2012. The report details a specific share repurchase transaction executed on November 8, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 700,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,385.0 pence per share; lowest price paid was 1,372.5 pence per share.
- Treasury Holdings (Settled): 524,190,427 shares (9.63% of total issued share capital).
- Treasury Holdings (Including Unsettled): 527,640,427 shares (10.72% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,921,256,262 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 700,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.72% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (524,190,427 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding Treasury shares (4,921,256,262) for accurate voting rights calculations.
- Check the settlement status of the 700,000 shares purchased on November 8, 2012, to reconcile the difference between settled and total Treasury holdings.
- Review the remaining authority under the May 3, 2012 shareholder mandate for future buybacks.